Latest news with #Exosomes
Globe and Mail
19-05-2025
- Business
- Globe and Mail
Exosomes Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, ' Exosomes Pipeline Insight 2025 ' report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Exosomes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Discover the latest drugs and treatment options in the Exosomes Pipeline. Dive into DelveInsight's comprehensive report today! @ Exosomes Pipeline Outlook Key Takeaways from the Exosomes Pipeline Report In April 2025, Aegle Therapeutics announced a study, with intra-subject paired- wound control, intended to assess the safety and preliminary efficacy of administering EVs derived from allogeneic MSCs to 10-50 cm2 wounds in RDEB subjects with wounds persisting for at least four weeks. DelveInsight's Exosomes pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Exosomes treatment. The leading Exosomes Companies such as Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Promising Exosomes Pipeline Therapies such as Anlotinib, AGLE 102, TISSEEL, and others. Stay ahead with the most recent pipeline outlook for Exosomes. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Exosomes Treatment Drugs Exosomes Emerging Drugs Profile ExoFlo: Direct Biologics ExoFlo is an acellular human bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle (EV) product produced with a proprietary EV platform technology by Direct Biologics, LLC. Containing signaling molecules from bone marrow MSCs, ExoFlo harnesses the anti-inflammatory and regenerative properties of bone marrow MSCs without the cost, complexity, and limitations of scale associated with stem cell transplantation. EXO-CD24: Nano24 EXO-CD24 (CovenD24), is an investigational drug being developed by Nano24. The company has developed a new anti-inflammatory drug, EXO-CD24, a combination of an immune checkpoint (CD24) and a delivery platform (exosomes). CD24 inhibits the NF-kB pathway and the production of cytokines/chemokines. EXO-CD24 discriminates damage from pathogen-associated molecular patterns (DAMPs and PAMPs) and therefore does not interfere with viral clearance. EXO-CD24 was produced and purified from CD24-expressing 293-TREx cells. Exosomes displaying murine CD24 (mCD24) were also created. AGLE-102: Aegle Therapeutics AGLE 102 is an allogeneic-derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material, and regenerative healing factors to diseased and damaged tissue. The drug is being developed in the Phase I/II stage of its development for the treatment of Burns and Epidermolysis bullosa dystrophica. The drug is also in the preclinical stage of its development for the Graft vs. Host Disease. Progenza: Cambium Bio Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing. Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose-derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. EV-101: EV Therapeutics EV Therapeutics is a pre-clinical stage immuno-oncology biotechnology company devoted to developing first-in-class therapies based on modified tumor extracellular vesicles (mTEVs) to significantly transform cancer therapy and other unmet medical needs that are addressable with its proprietary technology platform. The leading candidate EV101, has demonstrated pre-clinical efficacy across solid tumor and advanced metastatic animal models both as a monotherapy and combination therapy with checkpoint inhibitors. The Exosomes Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Exosomes with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Exosomes Treatment. Exosomes Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Exosomes Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Exosomes market Explore groundbreaking therapies and clinical trials in the Exosomes Pipeline. Access DelveInsight's detailed report now! @ New Exosomes Drugs Exosomes Companies Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Exosomes Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Oral Intravenous Subcutaneous Parenteral Topical Exosomes Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Unveil the future of Exosomes Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Exosomes Market Drivers and Barriers Scope of the Exosomes Pipeline Report Coverage- Global Exosomes Companies- Capricor Therapeutics, Regeneus, Aegle Therapeutics, Innovex Therapeutics, Coya Therapeutics, EV Therapeutics, StemXO Therapeutics, Brexogen, ILIAS Biologics, Organicell Regenerative Medicine, Codiak BioSciences, Direct Biologics, and others. Exosomes therapies- Anlotinib, AGLE 102, TISSEEL, and others. Exosomes Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Exosomes Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Get the latest on Exosomes Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Exosomes Companies, Key Products and Unmet Needs Table of Content Introduction Executive Summary Exosomes : Overview Pipeline Therapeutics Therapeutic Assessment Exosomes – DelveInsight's Analytical Perspective Late Stage Products (Phase III) CAP-1002: Capricor Therapeutics Drug profiles in the detailed report….. Mid Stage Products (Phase II) Progenza: Regeneus Drug profiles in the detailed report….. Early Stage Products (Phase I/II) AGLE 102: Aegle Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug Name: Company Name Drug profiles in the detailed report….. Inactive Products Exosomes Key Companies Exosomes Key Products Exosomes - Unmet Needs Exosomes - Market Drivers and Barriers Exosomes - Future Perspectives and Conclusion Exosomes Analyst Views Exosomes Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Metro
17-05-2025
- Health
- Metro
This serum by The INKEY List is clinically-proven to boost the skin's glow
Metro journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission – learn more Want that gorgeous post-facial glow, without the hefty price-tag that comes with stepping into a spa? Then allow us to formally introduce you to the Exosome Hydro-Glow Complex — a brightening and refining serum that promises salon-worthy results. One of the latest product releases from much-loved affordable brand, The INKEY List, this potent serum has been clinically proven to visibly boost glow, and smooth and renew the skin, in just 14 days. And it's all down to its seriously impressive formula. The undeniable star ingredient has to be the 3-million plant-derived Exosomes — which are essentially tiny messengers that stimulate the skin to boost collagen production by up to 300%, while also visibly repairing and soothing any inflammation. Meanwhile, nutrient-rich Prickly Pear Extract works to gently resurface the skin, while the tri-peptide Kollaren™ smooths and improves firmness. Finally, a clever blend of hyaluronic acid and ectoin work together to support the skin's barrier with up to 12 hours of hydration. Basically a facial in a bottle, this serum strives to leave your skin looking its most glowy and radiant. Alongside other potent actives, it's formulated with Exosomes —an advanced skin rejuvenation technology once exclusively reserved for medi-clinics. Silky and lightweight, the serum sinks effortlessly into the skin, and layers seamlessly under other skincare products. BUY NOW FOR £20 Despite only launching in April, it's already racked up hundreds of 5* reviews — with customers appearing genuinely shocked at just how much of an impact it's already had on their skin. 'I only started using it a week ago, but this magic potion has given me a brighter, even toned, youthful, and glowing look,' writes one happy customer. 'Three people have already commented on how healthy I look. Definitely add it to your basket!' More Trending In fact, the only real complaints we've seen are predominantly about the bottle's pump — which some seem to say can be a little faulty at times. But for lit-from-within skin for £20, we'll put up with slightly finicky packaging. Sold. Follow Metro across our social channels, on Facebook, Twitter and Instagram Share your views in the comments below MORE: Struggling with rosacea? This highly rated skincare range could be your new go-to MORE: Sun's out, SPF's out! Bulldog Skincare launch new UV moisturiser that's perfectly timed for the sunshine MORE: Pimple patches remain a cult skincare saviour – and here are the best to buy now
India Today
12-05-2025
- Health
- India Today
How skincare is now tied closely to overall wellbeing
Skincare is evolving beyond surface treatments, now viewed as an essential part of overall wellbeing. Experts highlight how internal health—like diet, hormones, stress, and sleep—deeply impact the skin. As a result, modern skincare combines medical science with holistic practices, addressing root causes like inflammation, gut imbalance, or emotional health. This shift reflects a growing awareness that glowing skin often starts from within, and true beauty is a reflection of internal balance and SCIENCE WITH COMPASSIONATE CAREIn a significant leap forward for holistic skincare and wellness in India, skincare is no longer just about appearance—it's increasingly linked to overall well-being. From gut health to stress levels, modern skincare approaches consider internal factors, blending science with lifestyle to promote long-term skin health and holistic Today spoke to Dr. Amit Bhasin and Dr. Aarti Bhasin about the brand's latest milestone and what it means for the future of wellness in India. PRIV Luxe focusses not just on what's visible, but also on the underlying causes of skin and wellness concerns. The new clinic is more than just a luxurious skincare space—it's a reflection of PRIV's philosophy that beauty is rooted in balance, both internal and external. With a comprehensive approach that incorporates dermatology, dietetics, physiotherapy, psychology, Ayurveda, and internal medicine, the clinic aims to promote lasting health and natural BEAUTY THROUGH BALANCEadvertisementOne of the clinic's standout offerings is the authentic Korean PDRN + Exosome therapy—a revolutionary regenerative skin treatment now introduced in India for the first time. This combination of PDRN (Polydeoxyribonucleotide), derived from salmon DNA, and Exosomes, nano-sized messengers rich in growth factors and peptides, works at the cellular level to deeply hydrate, repair, and rejuvenate the skin.'At PRIV Luxe, we believe true luxury lies in feeling your best—inside and out,' said Dr. Amit Bhasin, Managing Director of PRIV Luxe. 'PDRN + Exosomes represents a breakthrough in skin healing, and we are proud to be the first in India to introduce the authentic Korean formulation. "My focus has always been on results that enhance one's natural beauty—refined, subtle, and personal.'In addition to the science-backed innovations, the PRIV philosophy prioritizes individualized treatment plans. Every patient's journey is crafted with intention, addressing not only aesthetic needs but also concerns like hormonal imbalances, gut health, and emotional well-being.'What makes PRIV special is the way we combine precision with empathy,' said Dr. Aarti Bhasin, CEO of PRIV Luxe. 'We don't believe in one-size-fits-all. Every skin tells a story, and we take the time to listen. PDRN fits perfectly into this philosophy—gentle, effective, and in harmony with the skin.'advertisementThe clinic offers a wide array of advanced treatments including HydraFacial MD, Glass Glow Facials, Skin Boosters like Hyaluronic Acid and Polynucleotides, Morpheus8, Baby Botox, PRP, IV therapies, and more. Each treatment is selected for its ability to produce natural-looking results that enhance, rather than alter, the patient's India's wellness landscape continues to evolve, PRIV Luxe's latest launch underscores a growing shift towards integrative, personalised care. The Vasant Vihar clinic isn't just another beauty centre—it's a sanctuary for self-renewal, merging science, artistry, and compassion at every Amit Bhasin is the Founder and Managing Director of PRIV Skin & Wellness Clinic. He is a leading celebrity cosmetologist and dermatologist known for his work in face sculpting and regenerative Aarti Bhasin is the CEO of PRIV Skin & Wellness Clinic. A dental surgeon and aesthetic wellness expert, she leads the clinic's integrative approach to holistic skincare continues to align with overall wellness, it's clear that the path to healthy, radiant skin goes far beyond creams and treatments. Today, beauty is increasingly defined by balance—nourishing the body, mind, and skin together. This integrated approach marks a meaningful shift toward long-lasting results and authentic self-care. advertisement
Yahoo
17-02-2025
- Business
- Yahoo
Welbloom Bio-Tech to Showcase Exclusive Innovations at NPEW 2025: Ergothioneine and Anti-Aging Formulas Take Center Stage
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- Ergothioneine, known for their exceptional nutritional value, have been gaining significant global attention as a key ingredient in dietary supplements. According to market data, the global Ergothioneine supplement market is projected to reach USD 34.3 billion in 2024 and grow to USD 47.2 billion by 2028, highlighting vast consumer demand and market potential. Empowering Brands from Production to Sustainability Welbloom Bio-Tech, a leading Taiwanese contract development and manufacturing organization (CDMO) specializing in dietary supplements, is set to exhibit at the upcoming Natural Products Expo West (NPEW) in March. The company will unveil two innovative products—Wel-EGT® and Wel-Revive®—addressing the evolving health and wellness trends. Founded in 1999, Welbloom Bio-Tech comprises a team of professionals with backgrounds in pharmaceuticals, food science, and nutrition. The company operates an NSF-certified manufacturing facility, offering tailored solutions across the entire product lifecycle, from formulation development and production to training and education. Welbloom Bio-Tech takes pride in its proprietary FRESH-Jelly® technology, an industry-first patented delivery format. The company's commitment to sustainability is further demonstrated through its newly established LEED Silver-certified facility, which emphasizes the use of local ingredients and eco-friendly packaging while achieving carbon reduction goals. Welbloom Showcasing New Exosome Technology The company's flagship product, Wel-EGT®, leverages a proprietary mushroom Exosomes extraction technology enriched with amino acids, providing rapid nutrient absorption and boasting a remarkable 92% free radical scavenging rate per milliliter. In response to the aging population trend, Welbloom Bio-Tech will also unveil Wel-Revive®, a powerful anti-aging supplement formulated with turmeric, onion, and strawberry extracts. This compound formula is designed to combat oxidative stress and cellular aging, delivering noticeable results within just four weeks of use. NPEW will take place from March 5 to March 7 in Anaheim, California, where Welbloom Bio-Tech will exhibit at Hall D, Booth #3367. Industry professionals interested in exploring the latest innovations, especially the application of Exosomes in ingredients and formulations, are welcome to visit the booth or contact Jenny Zhu at service@ for further inquiries and collaboration opportunities. Media ContactJenny Zhu+886 2 33225555390339@ View original content to download multimedia: SOURCE Welbloom Bio-Tech Sign in to access your portfolio
